Completed PHASE1 INTERVENTIONAL 4-arm NCT03125473

Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers

A Phase 1b, Open-Label, Dose-Optimization Trial of an Adenoviral-vector Based Norovirus Vaccine (VXA-G1.1-NN) Expressing GI.1 VP1 and dsRNA Adjuvant Administered Orally to Healthy Volunteers

Sponsor: Vaxart

Conditions Norovirus Gastroenteritis

Interventions VXA-G1.1-NN Oral Vaccine

Updated 5 times since 2017 Last updated: May 29, 2018 Started: Apr 7, 2017 Primary completion: Jul 1, 2017 Completion: May 6, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Norovirus Gastroenteritis, this trial is completed. The trial is conducted by Vaxart and has accumulated 5 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Jun 2017 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Apr 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vaxart

Data source: Vaxart

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lincoln, United States